BioPharm International is the longest-running peer-reviewed publication dedicated to your work.
Recently we announced the appointment of Michelle Hoffman as Editorial Director of Advanstar's Pharmaceutical Drug Development and Manufacturing Group, which now includes BioPharm International, Pharmaceutical Technology, Pharmaceutical Technology Europe, and the IVT Journals. I am pleased to join Ms. Hoffman as BioPharm International's new publisher.
Allen Basis
It is exciting to work with an editor whose curriculum vita matches our tagline, "The Science & Business of Pharmaceuticals." Michelle's appointment and my employment and dedication to BioPharm International are examples of an evolving list of investments Advanstar Communications, our parent, is making in the brand. With more than 20 years of media management, I am dedicated to developing new and innovative ways of delivering the content you've come to depend on in print and online.
BioPharm International is the longest-running peer-reviewed publication dedicated to facilitating your work in the development and manufacturing of biotherapeutics and managing related business issues. Our goal is to provide the most up-to-date, reliable, and insightful information available to you in the biopharmaceutical market. To ensure that we meet your needs, I will seek your opinions about our performance.
We strive to equip you to manage your technical and business challenges effectively, but if we can serve you better with more news and information on tools, techniques, or business, we invite you to please let us know. Please drop us a line and be sure to look for us at industry conferences and expos throughout the year.
All the best,
Allen Basis is the publisher of BioPharm International, abasis@advanstar.com.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.